2026 ICD-10-CM Diagnosis Code D57.413Sickle-cell thalassemia, unspecified, with cerebral vascular involvement
ICD-10-CM Codes›D50–D89›D55-D59›D57
- Billable — Valid for Submission
- MCC — Major Complication or Comorbidity
- Risk Adjusts — HCC 108
- Chronic Condition
D57.413 is a billable ICD-10-CM diagnosis code for sickle-cell thalassemia, unspecified, with cerebral vascular involvement. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 791, 793, 811 through 812. As a secondary diagnosis, it counts as a major complication or comorbidity (MCC) and places an inpatient stay in the highest severity level of its MS-DRG family. It does not count, however, when the principal diagnosis is one of 47 closely related codes. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Sickle cell trait/anemia.
For Medicare Advantage risk adjustment, D57.413 maps to CMS-HCC Category 108 (Sickle Cell Disorders, Except Sickle Cell Anemia (Hb-SS) and Thalassemia Beta Zero; Beta Thalassemia Major) under the V28 model, adding a risk factor of about 0.146 for a community, non-dual, aged beneficiary in payment year 2026.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
D57.413 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2026.
Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Code Also
- , if applicable cerebral infarction I63
A "code also" note instructs that two codes may be required to fully describe a condition, but this note does not provide sequencing direction.
Index to Diseases and InjuriesGuidance
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Patient EducationClinical
Sickle Cell Disease
Sickle cell disease (SCD) is a group of inherited red blood cell disorders. If you have SCD, there is a problem with your hemoglobin. Hemoglobin is a protein in red blood cells that carries oxygen throughout the body. With SCD, the hemoglobin forms into stiff rods within the red blood cells. This changes the shape of the red blood cells.
The full article covers:
- What is sickle cell disease (SCD)?
- What causes sickle cell disease (SCD)?
- Who is more likely to have sickle cell disease (SCD)?
- What are the symptoms of sickle cell disease (SCD)?
- How is sickle cell disease (SCD) diagnosed?
- What are the treatments for sickle cell disease (SCD)?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Code History & ChangesHistory
Replacement D57.413 replaces the following previously assigned code(s):
- D57.419 - Sickle-cell thalassemia with crisis, unspecified
- D57.419 - Sickle-cell thalassemia, unspecified, with crisis
Questions About D57.413Overview
Is D57.413 (Sickle-cell thalassemia, unspecified, with crisis) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report sickle-cell thalassemia, unspecified, with cerebral vascular involvement on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does D57.413 group to?
When sickle-cell thalassemia, unspecified, with cerebral vascular involvement is the principal diagnosis on an inpatient stay, it groups to MS-DRG 791, 793, 811, 812, with relative weights from 0.9182 to 4.1696 depending on complications. Higher weights mean higher Medicare reimbursement.
Is D57.413 a CC or MCC?
CMS lists D57.413 as an MCC (major complication or comorbidity) for FY 2026. Reported as a secondary diagnosis, it places the inpatient stay in the highest-weighted DRG of its severity family. It does not count when the principal diagnosis is one of the 47 closely related codes in its exclusion list.
What HCC is D57.413?
D57.413 (sickle-cell thalassemia, unspecified, with cerebral vascular involvement) maps to CMS-HCC Category 108 (Sickle Cell Disorders, Except Sickle Cell Anemia (Hb-SS) and Thalassemia Beta Zero; Beta Thalassemia Major), commonly written as HCC 108, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2026. It mapped to HCC 46 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. It does not map to any RxHCC in the Part D prescription drug model.
Does D57.413 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, D57.413 adds a risk adjustment factor of about 0.146 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.098 to 0.416 depending on the payment segment). A more severe related category (HCC 107) supersedes it when both are reported. See the full factor table on the HCC 108 category page.
